Amyndas Pharmaceuticals

Amyndas Pharmaceuticals S.A. is a pharmaceutical company that develops effective complement therapies for inflammatory diseases and conditions based on its patented technology for regulating the complement system. This includes orphan diseases and conditions that represent unmet medical needs, where patients require better and safer therapies. The R&D pipeline of Amyndas Pharmaceuticals S.A. targets conditions such as transplantation, the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulonephritis, periodontitis, age-related macular degeneration, hemodialysis, and ischemia/reperfusion injury.